GlaxoSmithKline Price Target Lowered to GBX 1,800 at Deutsche Bank (GSK)
Analysts at Deutsche Bank dropped their target price on shares of GlaxoSmithKline (LON:GSK) from GBX 1,850 ($29.92) to GBX 1,800 ($29.11) in a research report issued to clients and investors on Thursday, ARN reports. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price target would indicate a potential upside of 14.61% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday. They now have a GBX 1,500 ($24.26) price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,600 ($25.87) price target on the stock. Finally, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Wednesday. They now have a GBX 1,870 ($30.24) price target on the stock. Five investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,630.52 ($26.37).
GlaxoSmithKline (LON:GSK) opened at 1577.00 on Thursday. GlaxoSmithKline has a one year low of GBX 1314.00 and a one year high of GBX 1816.00. The stock has a 50-day moving average of GBX 1596. and a 200-day moving average of GBX 1649.. The company’s market cap is £76.406 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.